Search company, investor...

Founded Year

2011

Stage

IPO | IPO

Total Raised

$140M

Date of IPO

7/16/2021

Market Cap

0.21B

Stock Price

4.30

About Sight Sciences

Sight Sciences is a growth-stage medical device company operating in the ophthalmology and optometry sectors. The company primarily focuses on transforming the treatment of glaucoma and dry eye disease. It was founded in 2011 and is based in Los Altos, California.

Headquarters Location

4040 Campbell Ave Suite 100

Los Altos, California, 94024,

United States

877-266-1144

Loading...

Loading...

Sight Sciences Patents

Sight Sciences has filed 63 patents.

The 3 most popular patent topics include:

  • diseases of the eye and adnexa
  • ophthalmology
  • eye surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/15/2023

1/23/2024

Diseases of the eye and adnexa, Eye surgery, Ophthalmology, Glaucoma, Surgical removal procedures

Grant

Application Date

3/15/2023

Grant Date

1/23/2024

Title

Related Topics

Diseases of the eye and adnexa, Eye surgery, Ophthalmology, Glaucoma, Surgical removal procedures

Status

Grant

Latest Sight Sciences News

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

Feb 22, 2024

Sight Sciences, Inc. MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, March 7, 2024. The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com , on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event. About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional technologies intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The Company's TearCare® System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company's SION® Surgical Instrument is a manually operated device available in the United States to be used in ophthalmic surgical procedures to excise trabecular meshwork. For more information, visit  http://www.sightsciences.com . Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI, OMNI ERGO, and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2024 Sight Sciences. All rights reserved. Media contact:

Sight Sciences Frequently Asked Questions (FAQ)

  • When was Sight Sciences founded?

    Sight Sciences was founded in 2011.

  • Where is Sight Sciences's headquarters?

    Sight Sciences's headquarters is located at 4040 Campbell Ave, Los Altos.

  • What is Sight Sciences's latest funding round?

    Sight Sciences's latest funding round is IPO.

  • How much did Sight Sciences raise?

    Sight Sciences raised a total of $140M.

  • Who are the investors of Sight Sciences?

    Investors of Sight Sciences include Scientific Health Development, Allegro Investment Fund, Paycheck Protection Program, D1 Capital Partners, MidCap Financial and 5 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.